Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256703 | 0.90 | RAB9A (0.70) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL24026399 | 0.85 | RAB9A (0.74) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30581066 | 0.84 | RAB9A (0.78) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7253225 | 0.82 | RAB9A (0.70) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21484720 | 0.82 | ABL1 (0.71) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL8230787 | 0.80 | HDAC1 (0.64) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5849033 | 0.80 | MAPK1 (0.79) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7239062 | 0.78 | RAB9A (1.00) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7239525 | 0.78 | RAB9A (0.86) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19497773 | 0.78 | GSTO1 (1.00) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902144-B2 | Carrier-molecule-affinitive substance which has an association constant KA relative to a carrier molecule greater than 103 M-1 via a noncovalent bond | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2011-03-08 | — | — | US | disclosed |
| EP-1272223-B1 | THERAPEUTIC AND DIAGNOSTIC LIGAND SYSTEMS COMPRISING TRANSPORT MOLECULE BINDING PROPERTIES AND MEDICAMENTS CONTAINING THE SAME | KTB TUMORFORSCHUNGS GMBH (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-20030185793-A1 | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | Vergell Medical S.A. (CH) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185793-A1 | Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same | SLCO1B1, SLCO1B3, SLCO1A2 | RAB9A 3897/4885NPC1 268/4885ALDH1A1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.